Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

APREA THERAPEUTICS, INC.

(APRE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Aprea Therapeutics : HC Wainwright Adjusts Aprea Therapeutics' Price Target to $4 from $6, Keeps Neutral Rating

08/16/2021 | 09:42am EDT


© MT Newswires 2021
All news about APREA THERAPEUTICS, INC.
10/15APREA THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
10/15Aprea Therapeutics, Inc. Announces Resignation of Johan Christenson from the Board of D..
CI
10/05INSIDER SELL : Aprea Therapeutics
MT
09/22INSIDER SELL : Aprea Therapeutics
MT
09/20APREA THERAPEUTICS : Presents Data From Phase 1/2 Trial of Eprenetapopt (APR-246) in Advan..
AQ
09/20Aprea Therapeutics, Inc. Presents Data From Phase 1/2 Trial of Eprenetapopt (APR-246) i..
CI
09/20Top Premarket Gainers
MT
09/20APREA THERAPEUTICS, INC.(NASDAQGS : APRE) dropped from S&P Global BMI Index
CI
09/14APREA THERAPEUTICS : to Present Data from Phase 1/2 Trial of Eprenetapopt in Advanced Soli..
AQ
09/14Aprea Therapeutics to Present Data from Phase 1/2 Trial of Eprenetapopt in Advanced Sol..
CI
More news
Analyst Recommendations on APREA THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -37,3 M - -
Net cash 2021 56,2 M - -
P/E ratio 2021 -2,91x
Yield 2021 -
Capitalization 108 M 108 M -
EV / Sales 2021 -
EV / Sales 2022 -
Nbr of Employees 11
Free-Float 89,9%
Chart APREA THERAPEUTICS, INC.
Duration : Period :
Aprea Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends APREA THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 5
Last Close Price 5,11 $
Average target price 4,00 $
Spread / Average Target -21,7%
EPS Revisions
Managers and Directors
Christian S. Schade Chairman, President & Chief Executive Officer
Scott M. Coiante Chief Financial Officer, Secretary & Senior VP
Eyal C. Attar Chief Medical Officer & Senior Vice President
Lars Abrahmsén Chief Scientific Officer & Senior Vice President
Johan Rutger Christenson Independent Director
Sector and Competitors
1st jan.Capi. (M$)
APREA THERAPEUTICS, INC.3.86%108
MODERNA, INC.225.04%137 066
LONZA GROUP AG32.03%60 786
IQVIA HOLDINGS INC.42.23%48 830
SEAGEN INC.-0.71%31 638
CELLTRION, INC.-39.42%25 233